Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution
Authors
Keywords
-
Journal
Molecular Oncology
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-06-07
DOI
10.1002/1878-0261.12741
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Characterization of PD-L1 protein expression and CD8+ tumor-infiltrating lymphocyte density, and their associations with clinical outcome in small-cell lung cancer
- (2020) Yajun Sun et al. Translational Lung Cancer Research
- Comparative expression analysis in small cell lung carcinoma reveals neuroendocrine pattern change in primary tumor versus lymph node metastases
- (2020) Zoltan Lohinai et al. Translational Lung Cancer Research
- Prognostic Impact of Tumor-Infiltrating Lymphocytes and Neutrophils on Survival of Patients with Upfront Resection of Pancreatic Cancer
- (2019) Rainer Miksch et al. Cancers
- Indoleamine 2,3-Dioxygenase Activity in Chlamydia muridarum and Chlamydia pneumoniae Infected Mouse Lung Tissues
- (2019) Dezső P. Virok et al. Frontiers in Cellular and Infection Microbiology
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
- (2019) Luis Paz-Ares et al. LANCET
- MHC-II neoantigens shape tumour immunity and response to immunotherapy
- (2019) Elise Alspach et al. NATURE
- Indoleamine-2,3-Dioxygenase in Non–Small Cell Lung Cancer
- (2018) Ashley Volaric et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
- (2018) Matthew D. Hellmann et al. CANCER CELL
- High IDO-1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma
- (2018) Andreas Seeber et al. CANCER SCIENCE
- MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
- (2018) Scott J. Rodig et al. Science Translational Medicine
- Prognostic significance of immune cells in non-small cell lung cancer: meta-analysis
- (2018) Ross A. Soo et al. Oncotarget
- The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy
- (2018) Lilla Hornyák et al. Frontiers in Immunology
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- (2018) Leora Horn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas
- (2017) Guoying Zhou et al. GASTROENTEROLOGY
- MHC class II expression in lung cancer
- (2017) Yayi He et al. LUNG CANCER
- Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer
- (2017) Karen McColl et al. Oncotarget
- Tim-3 Expression on Tumor-Infiltrating PD-1 + CD8 + T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma
- (2016) Clémence Granier et al. CANCER RESEARCH
- Loss ofYAP1defines neuroendocrine differentiation of lung tumors
- (2016) Takeshi Ito et al. CANCER SCIENCE
- Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer
- (2016) Kurt A. Schalper et al. CLINICAL CANCER RESEARCH
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
- (2016) Scott J Antonia et al. LANCET ONCOLOGY
- Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes
- (2016) A. Forero et al. Cancer Immunology Research
- TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients
- (2015) Joe-Marc Chauvin et al. JOURNAL OF CLINICAL INVESTIGATION
- Comprehensive genomic profiles of small cell lung cancer
- (2015) Julie George et al. NATURE
- An IL-27/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction
- (2015) Chen Zhu et al. Nature Communications
- Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma
- (2015) Valentina Bevelacqua et al. Oncotarget
- The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
- (2014) Robert J. Johnston et al. CANCER CELL
- New Insights into IDO Biology in Bacterial and Viral Infections
- (2014) Susanne V. Schmidt et al. Frontiers in Immunology
- Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring
- (2012) Anthony E Rizzardi et al. Diagnostic Pathology
- Indoleamine 2,3 dioxygenase and metabolic control of immune responses
- (2012) David H. Munn et al. TRENDS IN IMMUNOLOGY
- A Functional Role for Tumor Cell Heterogeneity in a Mouse Model of Small Cell Lung Cancer
- (2011) Joaquim Calbo et al. CANCER CELL
- Overexpression of Necl-5 correlates with unfavorable prognosis in patients with lung adenocarcinoma
- (2010) Reiko Nakai et al. CANCER SCIENCE
- Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non-Small Cell Lung Cancer
- (2008) K. I. Al-Shibli et al. CLINICAL CANCER RESEARCH
- Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape
- (2008) Jessica B. Katz et al. IMMUNOLOGICAL REVIEWS
- The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
- (2008) Xin Yu et al. NATURE IMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started